『Community Health Media』のカバーアート

Community Health Media

Community Health Media

著者： Community Health Media
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsCommunity Health Media 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

    Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh
    2026/09/01
    For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation.In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer.They explore which patients may benefit most from a T-DXd-based approach, how prior T-DXd exposure in early-stage disease could influence treatment at metastatic recurrence, and where THP may still have a role. The conversation also examines practical considerations around toxicity management, maintenance strategies in HER2+ disease, sequencing, and individualized treatment selection.Topics discussed:How CLEOPATRA and THP established the first-line standardDESTINY-Breast09 and T-DXd plus pertuzumabTreatment considerations for high-risk and HR+/HER2+ diseaseBrain metastases and high visceral disease burdenHow prior neoadjuvant or adjuvant T-DXd may influence treatmentManaging nausea, fatigue, and ILD with T-DXdDose modifications and maintaining quality of life with T-DXdPATINA and HER2CLIMB-05 maintenance approachesTreatment sequencing after first-line T-DXd plus pertuzumab▶️ Watch the full conversation and subscribe to Community Health Media for more expert perspectives on the latest research and evolving approaches in cancer care.#CHMConversations #SonyaReid #ShrutiSingh #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #TrastuzumabDeruxtecan #BreastCancer #BreastOncology #MedicalOncology #CommunityHealthMedia– Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast... • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o– Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    29 分
  • This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

    This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran
    2026/08/13

    Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer?


    At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC.


    The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 status. Dr. Damodaran also examines efficacy, toxicity, sequencing, and the practical tradeoffs that may influence which ADC clinicians choose.


    Topics discussed:

    • Historical first-line treatment of metastatic TNBC
    • TROPION-Breast02 and Dato-DXd
    • ASCENT-03 and sacituzumab govitecan in PD-L1-negative disease
    • ASCENT-04 and sacituzumab govitecan plus pembrolizumab
    • Progression-free survival, overall survival, and response rates
    • Toxicity differences between Dato-DXd and sacituzumab govitecan
    • Stomatitis, ocular toxicity, neutropenia, and supportive care
    • Whether TROP-2 expression should guide treatment
    • BRCA mutations and where PARP inhibitors may still fit
    • CNS activity and intracranial disease
    • Choosing between Dato-DXd and sacituzumab govitecan
    • ADCs sequencing


    The presentation concludes with a practical discussion on one of the biggest questions in TNBC today: If both ADCs are effective, how should clinicians choose between them?


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #SenthilDamodaran #TripleNegativeBreastCancer #TNBC #ADC #DatoDXd #SacituzumabGovitecan #TROPIONBreast02 #ASCENT03 #ASCENT04 #MedicalOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    25 分
  • This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

    This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi
    2026/08/13

    How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves?


    At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen.


    From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference.


    Topics discussed:

    • The evolution of first-line HER2-positive metastatic breast cancer treatment
    • CLEOPATRA and the foundation of modern HER2-directed therapy
    • PATINA and the addition of palbociclib in HR+/HER2+ disease
    • DESTINY-Breast09 and T-DXd plus pertuzumab
    • Depth and duration of response with T-DXd
    • HER2CLIMB-05 and tucatinib maintenance
    • ILD, transaminitis, and other treatment-related toxicities
    • Patient-reported outcomes and quality of life
    • Selecting treatment based on ER status, CNS disease, disease burden, and molecular profile
    • T-DXd duration and the possibility of induction-maintenance strategies
    • How PATINA and HER2CLIMB-05 could inform maintenance therapy


    The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient?


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    21 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません